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Abstract
Introduction: Because of its relevance to the functioning of the central nervous system, brain-derived neurotrophic
factor (BDNF) has been implicated in the pathogenesis of different neuropsychiatric diseases. Whether the BDNF
level can be a marker of brain dysfunction and thus predict mortality in critically ill patients is not known. Thus we
aimed to determine whether the plasma levels of BDNF are associated with morbidity and mortality in critically ill
patients.
Methods: Healthy volunteers (n = 40) and consecutive patients older than 18 years (n = 76) admitted for more
than 24 hours in an Intensive Care Unit (ICU) in a University hospital between July and October 2010 were
included in the present study. First blood samples were collected within 12 hours of enrollment (D0), and a second
sample, 48 hours after (D2) for determination of plasma BDNF levels. The relation between BDNF levels and
mortality was the primary outcome. The secondary outcomes were the relation between BDNF levels and delirium
and coma-free days (DCFD) and ICU and hospital length of stay (LOS).
Results: Admission plasma levels of BDNF were higher in ICU patients when compared with healthy volunteers
(1,536 (962) versus 6,565 (2,838) pg/ml). The mean BDNF D2 was significantly lower in nonsurvivor patients (5,865
(2,662) versus 6,741 (2,356) pg/ml). After adjusting for covariates, BDNF levels, the need for mechanical ventilation,
and sepsis were associated with mortality. Even in patients without clinically detectable brain dysfunction, lower
BDNF D2 levels were associated with mortality. BDNF D2 had a mild correlation to DCFD (r = 0.44), but not to ICU
and hospital LOS. In addition, plasma BDNF did not correlate to different plasma cytokines and platelets levels.
Conclusions: The plasma levels of BDNF were independently associated with mortality, even in the absence of
clinically detectable brain dysfunction.
Introduction
Neurotrophins are considered to play a major role in
neural function including survival, development, and
plasticity. Brain-derived neurotrophic factor (BDNF) is
the most abundant neurotrophin in the mammalian cen-
tral nervous system (CNS). BDNF protects the CNS
from injury, at least in part, by inhibiting apoptosis [1]
and by stimulating sprouting and neuronal reorganiza-
tion [2]. Because of its relevance to the functioning of
the CNS, BDNF has been implicated in the pathogenesis
of different neuropsychiatric diseases, including depres-
sion, brain trauma, and schizophrenia [3-5]. Recently,
BDNF was implicated in metabolic regulation [6], in the
development of lung diseases [7], and in the support of
hematopoiesis [8].
Brain dysfunction is a frequent complication of the criti-
cally ill patients. It is manifested mainly as coma or delir-
ium and has a great impact on morbidity and mortality of
critically ill patients. Despite its importance, delirium is
frequently underdiagnosed, even when systematically
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assessed with validated tools [9]. Thus, the search for bio-
markers of brain dysfunction is an important field in criti-
cal care research.
An increase in the levels of S100b (a calcium-binding
protein expressed in the cytoplasm of astroglia and
Schwann cells) had a positive correlation with lactate
levels and negatively with mean arterial pressure in criti-
cally ill patients without evident brain injury [10]. In
addition, neuronal specific enolase (NSE) and S100b did
not correlate to outcome in critically ill patients [11].
We demonstrated, in a case-control study, that BDNF
was associated with delirium occurrence, but not with
mortality, in this subgroup of patients [12]. If BDNF
levels can be a marker of subclinical brain dysfunction
and thus predict morbidity and mortality in critically ill
patients is not known. We hypothesized that, even in
the absence of clinically detectable brain dysfunction,
plasma levels of BDNF are associated with morbidity
and mortality in critically ill patients.
Materials and methods
Patients
A prospective cohort study was conducted in a conveni-
ence sample of patients older than 18 years admitted for
more than 24 hours to an ICU in a University hospital
between July and October 2010. Patients were excluded
if they had persistent coma or if they were admitted as a
result of brain trauma, postcardiac arrest, or other neu-
rologic reason (for example, stroke). Forty healthy
volunteers paired for sex and age were included, and
fasting blood was collected to determine the plasma
levels of BDNF. Hospital Sao José and Universidade do
Extremo Sul Catarinense review boards approved this
study. Informed consent was obtained from all patients
or their relatives before study inclusion.
Procedures
Demographic and clinical variables were collected and
allowed us to determine the Acute Physiology and Chronic
Health Evaluation (APACHE) II score [13] and the
Sequential Organ Failure Assessment (SOFA) score [14].
Severe sepsis and septic shock were defined according to
internationally agreed-on criteria [15]. Patients were
screened for delirium twice a day until ICU discharge by
using the Confusion Assessment Method for the Intensive
Care Unit (CAM-ICU) [16], by trained researchers.
Patients were diagnosed with delirium when they had at
least one positive CAM-ICU screening. Coma was defined
as a Richmond Agitation Sedation Scale (RASS) score of
-4 or -5. Clinically detectable brain dysfunction was
defined as the presence of either delirium or coma. The
first blood sample was collected within 12 hours of ICU
admission (D0), and a second one, 48 hours after (D2).
Blood was collected in Vacutainers with citrate and
immediately centrifuged at 3,000 g for 10 minutes, at 4°C.
The plasma was collected and stored at -80°C. Plasma
levels of BDNF and soluble tumor necrosis factor recep-
tors (STNFR) 1 and 2, interleukin (IL)-1b, IL-6, and IL-10
were measured with enzyme-linked immunosorbent assay
(ELISA), according to the procedures supplied by the
manufacturer (DuoSet; R&D Systems, Minneapolis, MN,
USA). All samples were assayed in duplicate. Lower detec-
tion limits for BDNF, sTNFRs, IL-1, IL-6, and IL-10 were
5, 10, 3, 3, and 6 pg/ml, respectively. Concentration was
expressed as pictograms per milliliter.
The relation between BDNF levels and mortality was
the primary outcome. As secondary outcome, we chose
the relation between BDNF levels and DCFD (that indi-
cate the days during the study period that a patient was
alive and free of acute brain dysfunction), ICU, and hos-
pital length of stay (LOS). Once BDNF could be related
to the inflammatory response and released from platelets,
the correlation between plasma levels of BDNF and dif-
ferent inflammatory molecules, as well platelets levels,
was determined.
Statistical analysis
All variables were tested for normality by using the Kol-
mogorov-Smirnov test. Differences in baseline characteris-
tics and BDNF levels between survivor and nonsurvivor
patients and between healthy volunteers and ICU patients
were tested by using c2 tests and the t test or Mann-Whit-
ney test. The area under receiver operating characteristic
(AUROC) curve was used to evaluate the ability of BDNF
to predict mortality.
The percentage variation of BDNF was calculated by
using the formula ((BDNF D2 - BNDF D0)/BDNF D0 ×
100) and dichotomized into “decrease” or “no decrease.”
Decrease was considered a reduction compared with D0
levels higher than 25%. To examine the association
between BDNF and mortality, a binary logistic regression
was performed. The model was adjusted for physiological
changes that would confound the relation between BDNF
and survival. Thus disease severity, age, need for mechani-
cal ventilation, sepsis, need for vasoactive drugs, and need
for sedation were incorporated into the model. The need
for vasoactive drugs is already incorporated in the SOFA
score. Thus, to avoid double-counting, it was not used as a
separate covariate in the model. Co-linearity was found
between the use of sedation and mechanical ventilation.
Thus the model used the SOFA score (and not the
APACHE score, as a variable associated with disease sever-
ity), age, need for mechanical ventilation, sepsis, and BDNF
levels. BDNF entered into the model as the odds among
patients at the 25th percentile of BDNF levels versus all
other quartiles grouped (a more clinically relevant
approach: Model 1) or as the generally used 1-unit change
in its D2 levels (Model 2).
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The correlation between BDNF and DCFD, ICU, or
hospital LOS was determined by the Pearson test. A mul-
tivariate linear regression was performed to determine
the association between plasma BDNF and DCFD, and it
included the same parameters described for the binary
regression. The correlation between plasma BDNF and
plasma cytokines or platelet levels was performed with
the Pearson test. A sample size of 17 patients in each
group was necessary to detect a 50% difference in bio-
markers between groups. Statistical significance was
defined as a P value < 0.05.
Results
In total, 76 patients were included, 56 survivor and 20
nonsurvivor. The differences between survivors and non-
survivors are presented in Table 1. The main admission
reasons were cardiovascular (n = 9), respiratory failure
(n = 13), sepsis (n = 25), and postoperative monitoring
(n = 17), with no statistical significant differences
between survivors and nonsurvivors (P = 0.321). Only
four patients received immunosuppressants, and nine
patients were given renal replacement therapy, with no
statistical significant differences between survivors and
nonsurvivors (P = 0.674 and P = 0.611, respectively).
BDNF D0 levels were higher when compared with those
of healthy volunteers (1,536 ± 962 versus 6,565 ± 2,838
pg/ml; P < 0.0001), but were not significantly different
when compared between survivors and nonsurvivors
(Table 1). In contrast, BDNF D2 levels were significantly
lower in nonsurvivor patients (Table 1), with an AUROC
curve to predict survival of 0.87 (0.78 to 0.95). This was
similar when BDNF levels were transformed as a percen-
tage variation (Table 1). After adjusting for covariates,
BDNF and the need for mechanical ventilation or sepsis
were associated with mortality (Table 2).
To ascertain further that the presence of clinically
detectable brain dysfunction did not interfere in these
results, as an association between BDNF and mortality
could simply represent clinically detectable brain dys-
function, we analyzed the ability of BDNF to predict
outcome in patients without brain dysfunction. Even in
these patients, the levels of BDNF were associated with
mortality (Table 3), as well in the subgroup of patients
with clinically detectable brain dysfunction (Table 4).
A significant, but weak, correlation between BDNF D0
and DCFD (r = 0.31; P = 0.01), as well a mild correlation
between BDNF D2 and DCFD (r = 0.44; P < 0.001) were
observed In the linear regression BDNF D2 levels (unstan-
dardized B 6.95 (2.3 to 9.7); P = 0.002), but not BDFN D0
(unstandardized B 2.05 (-2.4 to 6.5); P = 0.36) and sepsis
(unstandardized B -3.4 (-6.7 to -0.08); P = 0.045) were
independently associated with DCFD. Plasma levels of
BDNF did not correlate to either ICU or hospital LOS
(data not shown). In addition, plasma levels of BDNF did
not correlate to any of the measured plasma cytokines or
to platelets levels (data not shown).
Table 1 Characteristics of patients enrolled in the present study
All patients (n = 76) Survivors (n = 56) Nonsurvivors (n = 20) P value
Age, years, mean (SD) 55 (19) 52 (19) 62 (16) 0.04
Sex, male, n 52 40 12 0.345
Admission, n
Surgical 27 20 7 0.954
Clinical 49 36 13
Origin, n
Ward 34 22 12 0.181
Emergency room 42 34 8
Sepsis, during ICU stay, n 39 23 16 0.003
APACHE II score, points, mean (SD) 19 (8) 18 (8) 20 (8) 0.319
SOFA admission, points, mean (SD) 6.6 (4.0) 6.0 (3.4) 8.3 (4.7) 0.03
Mechanical ventilation during ICU stay, n 46 29 17 0.008
Sedation during ICU stay, n 50 32 18 0.008
Vasopressor need during ICU stay, n 31 21 10 0.329
BDNF D0 mean (SD) 4,831 (3,366) 6,861 (2,764) 5,736 (2,951) 0.129
BDNF D2, mean (SD) 5,865 (2,661) 6,741 (2,356) 3,413 (1,813) < 0.0001
% variation BDNF, n
Decrease 19 8 11 0.001
No change/increase 57 48 9
APACHE II, Acute Physiology and Chronic Health Evaluation score; BDNF D0, brain-derived neurotrophic factor collected within 12 hours of enrollment; BDNF D2,
brain-derived neurotrophic factor collected 48 hours after intensive care admission; ICU, intensive care unit; SD, standard deviation; sepsis, severe sepsis and
septic shock; SOFA, sequential organ-failure assessment.
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Discussion
We demonstrate here that plasma levels of BDNF are
related to mortality, independent of the presence of
clinically detectable delirium, and to DCFD, but not to
ICU and hospital LOS.
BDNF is thought to play a major role in neural func-
tion, including survival and plasticity [17]. The majority
of the effects of BDNF are mediated by binding with its
specific receptor that is highly expressed in the adult
brain and is essential in survival of mature neurons [18].
The observation that the decrease in BDNF levels during
the ICU stay is related to mortality suggests that moni-
toring the levels of BDNF during the ICU stay can
improve our ability to predict death in these patients. In
addition, we demonstrate that critically ill patients pre-
sented higher BDNF plasma levels when compared with
healthy volunteers. We suppose that this is related to the
fact that BDNF is crucial for the recovering of brain after
an acute stress [19,20] and the decrease in the levels of
BDNF in nonsurvivors suggests the inability of these
patients to cope with acute stress [20]. It is possible that,
during critical illness, the central nervous system needs
higher levels of BDNF to maintain its function, and the
inability to maintain adequate levels of BDNF is asso-
ciated with brain dysfunction (either clinical or
subclinical).
Our results do not allow us to determine a direct rela-
tion between BDNF levels and mortality. Actually, the
late-onset BDNF-knockout mice grow at a normal rate
and can survive more than a year, but have several beha-
vioral deficits [21]. Thus, it seems that BDNF is not
essential for survival, at least in animals that are not sub-
mitted to stress. This is a relevant next step to be made,
to understand whether a direct association exists between
BDNF and survival or if our results represent only one
more marker of severity in ICU patients.
Brain-specific proteins are reliable markers of brain
injury, and predict outcome in head injury, stroke, and
postcardiac arrest [22-24]. Plasma levels of S100b and
NSE can predict early ICU mortality; plasma levels of
S100b measured at ICU admission are independent pre-
dictors of survival in sepsis patients [25]. In contrast,
Weigand et al. [26] demonstrated a relation between
plasma levels of NSE, but not S100b, and mortality in
sepsis patients [26]. In general ICU patients, we could
not demonstrate any significant relation between plasma
levels of these markers and mortality [11].
Some limitations occur in the use of S100b and NSE as
markers of brain injury in general ICU patients. Cell
death must occur for them to be released from the CNS,
but probably during nonprimary CNS diseases, large
amounts of cell death are not found [27]. Indeed, S100b
seems to be a marker of hypoperfusion in critically ill
patients [10]. We suggest that plasma levels of BDNF can
be a better marker of brain dysfunction in critically ill
patients, when compared with S100b and NSE, because it
is related to the ability of brain to recover from an injury,
and it is not just released from dead neurons. Actually,
neuronal activity is necessary to transcribe and release
BDNF from neurons, and critical illness-associated organ
failure can be characterized as a hypometabolic state with
Table 2 Multivariate analysis of characteristics associated
with mortality
OR (CI 95%) P value
Model 1
BDNF 25th quartile 12.7 (2.2 to 73) 0.004
Sepsis 6.3 (1.1 to 39) 0.04
Age 1.01 (0.98 to 1.06) 0.33
Admission SOFA 1.06 (0.87 to 1.31) 0.53
Mechanical ventilation 8.56 (0.92 to 79) 0.05
Model 2
BDNF D2 29 (4 to 200) 0.001
Sepsis 3.3 (0.56 to 20) 0.18
Age 1.04 (0.99 to 1.09) 0.09
Admission SOFA 0.91 (0.72 to 1.15) 0.46
Mechanical ventilation 14 (1.1 to 175) 0.038
Hosmer and Lemershow goodness-of-fit model 1, c2 = 2.2; P = 0.97; and
model 2, c2 = 1.9; P = 0.98. BDNF D2, brain-derived neurotrophic factor
collected 48 hours after intensive care admission; CI, confidence interval; OR,
odds ratio; SOFA, sequential organ-failure assessment.
Table 3 Brain-derived neurotrophic factor levels in the







BDNF D0, mean (SD) 6,811 (2,613) 5,970 (3,054) 0.437
BDNF D2, mean (SD) 6,736 (2,613) 3,115 (1,997) < 0.0001
% variation BDNF, n
Decrease 4 5 0.003
No change/increase 27 3
BDNF D0, brain-derived neurotrophic factor collected within 12 hours of
enrollment; BDNF D2, brain-derived neurotrophic factor collected 48 hours
after intensive care admission.
Table 4 Brain-derived neurotrophic factor levels in the







BDNF D0, mean (SD) 6,923 (2,994) 5,580 (3,006) 0.210
BDNF D2, mean (SD) 6,748 (2,594) 3,612 (1,741) < 0.0001
% variation BDNF, n
Decrease 4 6 0.049
No change/increase 21 6
BDNF D0, brain-derived neurotrophic factor collected within 12 hours of
enrollment; BDNF D2, brain-derived neurotrophic factor collected 48 hours
after intensive care admission.
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decreased mitochondrial activity and adenosine-5’-tri-
phosphate production [28], reinforcing the idea that the
decrease in plasma levels of BDNF can be a reflex of
brain dysfunction.
Some limitations must be pointed out. First, this is a
pilot investigation and may lack statistical power to
detect some clinically important associations. Because of
the relatively small sample size, only a limited number of
covariates could be incorporated into the regression
models. Second, production of BDNF occurs in periph-
eral tissues [29], and because we measured the levels of
BDNF in plasma, and not in cerebrospinal fluid, we can-
not provide a definitive confirmation of a brain-specific
source of BDNF. Despite this, BDNF can cross the blood-
brain barrier [30], and evidence indicates that plasma
levels of BDNF are related to its CNS levels, at least in
animals [31]. The release of BDNF by peripheral organs,
mainly the gut epithelia, is not related to a local function
of BDNF in these tissues, because, in general, they lack
both high- and low-affinity BDNF receptors [29]. There-
fore, it has been postulated that peripheral BDNF is
taken up by neurons of the central and peripheral ner-
vous system. In addition, the inflammatory response
seems to be involved in the release of BDNF in humans
[32], but we cannot find any statistically significant corre-
lation between the levels of BDNF and several cytokines.
This suggests that the decrease in plasma BDNF levels is
not related to the inflammatory response. BDNF can be
released from platelets, mainly during the clotting pro-
cess [33], so serum BDNF levels are higher when com-
pared with plasma BDNF levels [34]. Thus, because
platelets might serve as a reservoir for circulating BDNF
[35], the plasma levels of BDNF do not reflect platelet
levels, and this information could be important to under-
standing our results.
Conclusions
The plasma levels of BDNF are independently related to
mortality, even in the absence of clinically detectable
brain dysfunction. This suggests that the monitoring of
plasma levels of BDNF can improve our ability to predict
outcome in critically ill patients.
Key messages
• BDNF is suggested to be a surrogate of brain dys-
function in critically ill patients.
• BDNF plasma levels are independently associated
with mortality in critically ill patients.
Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; AUROC: area
under receiver operating characteristic; BDNF: brain-derived neurotrophic
factor; CAM-ICU: Confusion Assessment Method for the Intensive Care Unit;
CNS: central nervous system; DCFD: delirium-coma-free days; ELISA: enzyme-
linked immunosorbent assay; ICU: intensive care unit; IL: interleukin; LOS:
length of stay; NSE: neuron-specific enolase; RASS: Richmond Agitation
Sedation Scale; SOFA: Sequential Organ Failure Assessment; STNFR: soluble
tumor necrosis factor receptor.
Acknowledgements
This work was funded by NENASC project (PRONEX program CNPq/FAPESC);
National Institute of Science and Technology-Translational Medicine;
PROCAD Sepse-CAPES, and FAPEMIG.
Author details
1Laboratório de Fisiopatologia Experimental and Instituto Nacional de
Ciência e Tecnologia Translacional em Medicina, Programa de Pós-
Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da
Saúde, Universidade do Extremo Sul Catarinense, Av. Universitária, 1105,
Criciúma, 88806000, Brazil. 2Intensive Care Unit, Hospital São José, Cel. Pedro
Benedet, 630, Criciúma, 88801250, Brazil. 3Grupo de Neuroimunologia,
Laboratório de Imunofarmacologia, Departamento de Bioquímica e
Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas
Gerais, Av. Antonio Carlos, 6627, Belo Horizonte, 31270901, Brazil.
4Laboratório de Neurociências and Instituto Nacional de Ciência e
Tecnologia Translacional em Medicina, Programa de Pós-Graduação em
Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade
do Extremo Sul Catarinense, Av. Universitária, 1105, Criciúma, 88806000,
Brazil.
Authors’ contributions
CR, ALT, JQ, and FDP made substantial contributions to conception and
design of the study and were involved in drafting the manuscript. CDT,
CMC, VRG, and ASM made substantial contributions to the acquisition of
data, its analysis, and interpretation. All authors read and approved the
manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 18 September 2012 Revised: 9 November 2012
Accepted: 26 November 2012 Published: 17 December 2012
References
1. Counts SE, Mufson EJ: Noradrenaline activation of neurotrophic pathways
protects against neuronal amyloid toxicity. J Neurochem 2010,
113:649-660.
2. McAllister AK: Spatially restricted actions of BDNF. Neuron 2002,
36:549-550.
3. Teixeira AL, Barbosa IG, Diniz BS, Kummer A: Circulating levels of brain-
derived neurotrophic factor: correlation with mood, cognition and
motor function. Biomark Med 2012, 4:871-887.
4. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant’Anna M,
Klamt F, Moreira JC, de Bittencourt Pasquali MA, Fries GR, Quevedo J,
Gama CS, Post R: Peripheral biomarkers and illness activity in bipolar
disorder. J Psychiatr Res 2011, 45:156-161.
5. Chiaretti A, Piastra M, Polidori G, Di Rocco C, Caresta E, Antonelli A,
Amendola T, Aloe L: Correlation between neurotrophic factor expression
and outcome of children with severe traumatic brain injury. Intensive
Care Med 2003, 29:1329-1338.
6. Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM,
Driscoll I, Ferrucci L, Martin B, Mattson MP: Circulating brain-derived
neurotrophic factor and indices of metabolic and cardiovascular health:
data from the Baltimore Longitudinal Study of Aging. PLoS One 2010, 5:
e10099.
7. Müller GC, Pitrez PM, Teixeira AL, Pires PS, Jones MH, Stein RT, Bauer ME:
Plasma brain-derived neurotrophic factor levels are associated with
clinical severity in school age children with asthma. Clin Exp Allergy 2012,
40:1755-1759.
8. Rezaee F, Rellick SL, Piedimonte G, Akers SM, O’Leary HA, Martin K,
Craig MD, Gibson LF: Neurotrophins regulate bone marrow stromal cell
IL-6 expression through the MAPK pathway. PLoS One 2010, 5:e9690.
9. van Eijk MM, van den Boogaard M, van Marum RJ, Benner P,
Eikelenboom P, Honing ML, van der Hoven B, Horn J, Izaks GJ, Kalf A,
Karakus A, Klijn IA, Kuiper MA, de Leeuw FE, de Man T, van der Mast RC,
Ritter et al. Critical Care 2012, 16:R234
http://ccforum.com/content/16/6/R234
Page 5 of 6
Osse RJ, de Rooij SE, Spronk PE, van der Voort PH, van Gool WA, Slooter AJ:
Routine use of the confusion assessment method for the intensive care
unit: a multicenter study. Am J Respir Crit Care Med 2011, 184:340-344.
10. Routsi C, Stamataki E, Nanas S, Psachoulia C, Stathopoulos A, Koroneos A,
Zervou M, Jullien G, Roussos C: Increased levels of serum S100B protein
in critically ill patients without brain injury. Shock 2006, 26:20-24.
11. Macedo RC, Tomasi CD, Giombelli VR, Alves SC, Bristot MLU, Locks MFT,
Petronilho F, Grandi C, Quevedo J, Dal-Pizzol F, Ritter C: Lack of association
of S100β and neuron-specific enolase with mortality in critically ill
patients. Rev Bras Psiquiatr 2012.
12. Grandi C, Tomasi CD, Fernandes K, Stertz L, Kapczinski F, Quevedo J, Dal-
Pizzol F, Ritter C: Brain-derived neurotrophic factor and neuron-specific
enolase, but not S100β, levels are associated to the occurrence of
delirium in intensive care unit patients. J Crit Care 2011, 26:133-137.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of
disease classification system. Crit Care Med 1985, 13:818-829.
14. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM,
Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the
incidence of organ dysfunction/failure in intensive care units: results of
a multicenter, prospective study: Working group on “sepsis-related
problems” of the European Society of Intensive Care Medicine. Crit Care
Med 1998, 26:1793-1800.
15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J,
Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit
Care Med 2003, 31:1250-1256.
16. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, Speroff T,
Gautam S, Bernard GR, Inouye SK: Evaluation of delirium in critically ill
patients: validation of the Confusion Assessment Method for the
Intensive Care Unit (CAM-ICU). Crit Care Med 2001, 29:1370-1379.
17. Balaratnasingam S, Janca A: Brain derived neurotrophic factor: a novel
neurotrophin involved in psychiatric and neurological disorders.
Pharmacol Ther 2012, 134:116-124.
18. Autry AE, Monteggia LM: Brain-derived neurotrophic factor and
neuropsychiatric disorders. Pharmacol Rev 2012, 64:238-258.
19. Nagahara AH, Tuszynski MH: Potential therapeutic uses of BDNF in
neurological and psychiatric disorders. Nat Rev Drug Discov 2011,
10:209-219.
20. Yau SY, Lau BW, Zhang ED, Lee JC, Li A, Lee TM, Ching YP, Xu AM, So KF:
Effects of voluntary running on plasma levels of neurotrophins,
hippocampal cell proliferation and learning and memory in stressed
rats. Neuroscience 2012, 222:289-301.
21. Vigers AJ, Amin DS, Talley-Farnham T, Gorski JA, Xu B, Jones KR: Sustained
expression of brain-derived neurotrophic factor is required for
maintenance of dendritic spines and normal behavior. Neuroscience 2012,
212:1-18.
22. Mörtberg E, Zetterberg H, Nordmark J, Blennow K, Rosengren L,
Rubertsson S: S-100B is superior to NSE, BDNF and GFAP in predicting
outcome of resuscitation from cardiac arrest with hypothermia
treatment. Resuscitation 2011, 82:26-31.
23. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC, BRAIN Study Group:
Clinical usefulness of a biomarker-based diagnostic test for acute stroke:
the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke
2009, 40:77-85.
24. Metting Z, Wilczak N, Rodiger LA, Schaaf JM, van der Naalt J: GFAP and
S100B in the acute phase of mild traumatic brain injury. Neurology 2012,
78:1428-1433.
25. Nguyen DN, Spapen H, Su F, Schiettecatte J, Shi L, Hachimi-Idrissi S,
Huyghens L: Elevated serum levels of S-100beta protein and neuron-
specific enolase are associated with brain injury in patients with severe
sepsis and septic shock. Crit Care Med 2006, 34:1967-1974.
26. Weigand MA, Volkmann M, Schmidt H, Martin E, Böhrer H, Bardenheuer HJ:
Neuron-specific enolase as a marker of fatal outcome in patients with
severe sepsis or septic shock. Anesthesiology 2000, 92:905-907.
27. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP,
Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with
sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999,
27:1230-1251.
28. Singer M, De Santis V, Vitale D, Jeffcoate W: Multiorgan failure is an
adaptive, endocrine-mediated, metabolic response to overwhelming
systemic inflammation. Lancet 2004, 364:545-548.
29. Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, Botchkareva NV,
Paus R, Fischer A, Lewin GR, Renz H: Abundant production of brain-
derived neurotrophic factor by adult visceral epithelia: implications for
paracrine and target-derived neurotrophic functions. Am J Pathol 1999,
155:1183-1193.
30. Poduslo JF, Curran GL: Permeability at the blood-brain and blood-nerve
barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res
Mol Brain Res 1996, 36:280-286.
31. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-
derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002,
328:261-264.
32. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N,
Miorelli A, Navari S, Papadopoulos AS, Aitchison KJ, Morgan C, Murray RM,
Dazzan P, Pariante CM: Stress and inflammation reduce brain-derived
neurotrophic factor expression in first-episode psychosis: a pathway to
smaller hippocampal volume. J Clin Psychiatry 2011, 72:1677-1684.
33. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J,
Sun B, Tandon NN: Brain-derived neurotrophic factor is stored in human
platelets and released by agonist stimulation. Thromb Haemost 2002,
87:728-734.
34. Piccinni A, Marazziti D, Catena M, Domenici L, Del Debbio A, Bianchi C,
Mannari C, Martini C, Da Pozzo E, Schiavi E, Mariotti A, Roncaglia I, Palla A,
Consoli G, Giovannini L, Massimetti G, Dell’Osso L: Plasma and serum
brain-derived neurotrophic factor (BDNF) in depressed patients during 1
year of antidepressant treatments. J Affect Disord 2008, 105:279-283.
35. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-
Werner P, Virchow JC: The impact of age, weight and gender on BDNF
levels in human platelets and plasma. Neurobiol Aging 2005, 26:115-123.
doi:10.1186/cc11902
Cite this article as: Ritter et al.: Brain-derived neurotrophic factor plasma
levels are associated with mortality in critically ill patients even in the
absence of brain injury. Critical Care 2012 16:R234.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ritter et al. Critical Care 2012, 16:R234
http://ccforum.com/content/16/6/R234
Page 6 of 6
